Evaluation of FID 114657 in Sjogren's Syndrome Subjects
This study has been completed.
First Posted: March 3, 2010
Last Update Posted: February 2, 2012
Information provided by (Responsible Party):
The primary objective of this study is to assess the overall Sjogren's Syndrome subject's preference for a particular product. Dry eye symptom relief will also be evaluated based on clinical evaluation and a set of subject questionnaires.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Alcon Research:
Primary Outcome Measures:
- Preference based on subject's relief of dry eye [ Time Frame: 5 weeks ]
|Study Start Date:||February 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Experimental: FID 114657 (ORB Preserved Ocular Emulsion)
ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
Other: FID 114657 (ORB Preserved Ocular Emulsion)
Patients will dose as needed throughout the day (PRN) for 4 weeks.
Contacts and Locations
No Contacts or Locations Provided